Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound

Brain Tumor Clinical Trial

Official title:

A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in the Treatment of Brain Tumours With Doxorubicin

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02343991
• Other study ID #: BBB001
• Secondary ID: 215600
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 2014
• Est. completion date: July 2022

Study information

• Verified date: August 2021
• Source: InSightec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of BBB disruption using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent to increase the accumulation of doxorubicin in brain tumours and the adjacent brain using the ExAblate Transcranial system (220 kHz). Data will be collected to establish the basic safety of this type of treatment as the basis for later studies to evaluate its clinical efficacy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 10
• Est. completion date: July 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Men or women.

• Age between 18 and 70 years, inclusive.

• Able and willing to give informed consent.

• Size of the targeted portion of the tumour (i.e. prescribed ROT) is less than 2.5 cm in diameter (16 cm3). The non-targeted tumour tissue may exceed the targeted volume.

• Karnofsky rating 70-100

• ASA score 1-3.

• Able to communicate sensations during the ExAblate MRgFUS procedure.

• Able to attend all study visits (i.e., life expectancy of at least 3 months).

• At least 14 days passed since last brain surgery.

Exclusion Criteria:

• The sonication pathway to the tumour involves:

i. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp ii. Clips or other metallic implanted objects in the skull or the brain, except shunts

• The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema)

• Cardiac disease or unstable hemodynamics including:

i. Documented myocardial infarction within six months of enrolment ii. Unstable angina on medication iii. Congestive heart failure iv. Left ventricular ejection fraction below the lower limit of normal v. History of a hemodynamically unstable cardiac arrythmia vi. Cardiac pacemaker

• Severe hypertension (diastolic BP > 100 on medication)

• Anti-coagulant therapy, or medications known to increase risk of hemorrhage, (e.g.:ASA, non-steroidal anti-inflammatory drugs (NSAIDs), statins)

• History of a bleeding disorder, coagulopathy or with a history of spontaneous tumour hemorrhage

• Abnormal level of platelets (< 100000), PT (>14) or PTT (>36), and INR > 1.3

• Documented cerebral infarction within the past 12 months

• TIA in the last 1 month

• Cerebral or systemic vasculopathy

• Insulin-dependent diabetes mellitus

• Immunosuppression (corticosteroids to prevent/treat brain edema are permitted)

• Known sensitivity to gadolinium-DTPA

• Contraindications to MRI such as non-MRI-compatible implanted devices

• Large subjects not fitting comfortably into the MRI scanner (generally >250 lbs)

• Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia

• Untreated, uncontrolled sleep apnea

• Positive pregnancy test (for pre-menopausal women)

• Known life-threatening systemic disease

• Severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 and/or on dialysis

• Right to left or bi-directional cardiac shunt

• Previous full course of doxorubicin chemotherapy

• Allergy to eggs or egg products

Related Conditions & MeSH terms

• Brain Neoplasms
• Brain Tumor

Intervention

Device:
• Transcranial ExABlate
MR Guided Focused Ultrasound

Locations

Country	Name	City	State
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
InSightec

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Device and Procedure related adverse events	To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate transcranial treatment	At the time of ExAblate transcranial procedure
Secondary	Severity of Device and Procedure related adverse events	To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate transcranial treatment	At the time of ExAblate transcranial procedure